Prospective Grant of Exclusive License: The Development of Immunotoxins/Targeted Toxins for the Treatment of Human Cancers

Короткий зміст

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application 61/241,620 entitled "Development of an Immunotoxin in Which All B-Cell Epitopes Have Been Removed and Which Has High Cytotoxic Activity" [HHS Ref. E-269-2009/0-US-01], U.S. Patent Application 60/969,929 entitled "Deletions in Domain II of Pseudomonas Exotoxin A That Reduce Non-Specific Toxicity" [HHS Ref. E-292-2007/0- US-01], U.S. Patent Application 60/703,798 entitled "Mutated Pseudomonas Exotoxins with Reduced Antigenicity" [HHS Ref. E-262-2005/ 0-US-01], U.S. Patent Application 60/160,071 entitled "Immunoconjugates Having High Binding Affinity" [HHS Ref. E-139-1999/ 0-US-01], U.S. Patent Application 60/067,175 entitled "Antibodies, Including Fv Molecules, and Immunoconjugates Having High Binding Affinity for Mesothelin and Methods for Their Use" [HHS Ref. E-021- 1998/0-US-01], U.S. Patent Application 60/010,166 entitled "Molecular Cloning of Mesothelin, a Differentiation Antigen Present on Mesotheli